AB0457 Clinical equivalence in efficacy between abp 501 and adalimumab in patients with moderate to severe rheumatoid arthritis: a tipping point sensitivity analysis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.6855
Abstract: Background ABP 501 is the first approved biosimilar to adalimumab. Patient withdrawals from clinical trials can result in missing data, which may lead to loss of statistical power and bias of the treatment difference estimate.… read more here.
Keywords: amgen inc; tipping point; point sensitivity; abp 501 ... See more keywords